<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107354</url>
  </required_header>
  <id_info>
    <org_study_id>1334.00</org_study_id>
    <secondary_id>CDR0000407784</secondary_id>
    <nct_id>NCT00107354</nct_id>
  </id_info>
  <brief_title>Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant</brief_title>
  <official_title>Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the
      immune system in different ways and stop cancer cells from growing.

      PURPOSE: This phase I trial is studying the side effects of cellular adoptive immunotherapy
      in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, or
      myelodysplastic syndromes that relapsed after donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the toxic effects of adoptive immunotherapy comprising CD8-positive minor
           histocompatability antigen-specific cytotoxic T-lymphocytes in patients with acute
           myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes that
           relapsed after allogeneic hematopoietic stem cell transplantation.

      Secondary

        -  Determine the persistence of adoptively transfused T cells in vivo and assess their
           migration to the bone marrow in these patients.

        -  Determine the anti-leukemic activity of this therapy in these patients.

      OUTLINE: This is a pilot, open-label, nonrandomized study.

        -  Leukapheresis: Patients undergo leukapheresis to obtain peripheral blood mononuclear
           cells (PBMCs) before transplantation. Donors undergo leukapheresis to obtain PBMCs to
           use as feeder cells for generating adoptive immunotherapy. Patient PBMCs are combined
           with donor PBMCs and expanded in vitro to generate CD8-positive minor histocompatability
           antigen-specific cytotoxic T-lymphocytes (CTLs) for adoptive immunotherapy.

        -  Transplantation: Patients undergo allogeneic bone marrow or peripheral blood stem cell
           transplantation. Patients with a morphologic or flow cytometric relapse on or after day
           100 post-transplantation proceed to cytoreductive chemotherapy. Patients with a
           molecular or cytogenetic relapse on or after day 100 post-transplantation proceed
           directly to adoptive immunotherapy. Patients with relapsed disease before day 100
           post-transplantation are eligible to receive adoptive immunotherapy at a later date
           provided the patient continues to relapse and CTLs are available.

        -  Cytoreductive chemotherapy: The chemotherapy regimen for each patient is determined
           after consideration of prior chemotherapy, type of leukemia, and other clinical
           parameters. Two regimens to consider are:

             -  Mitoxantrone IV and etoposide IV on days -6 to -2

             -  High-dose cytarabine IV over 2 hours twice daily on days -6, -4, and -2 Patients
                achieving a complete remission after completion of cytoreductive chemotherapy
                proceed to adoptive immunotherapy.

        -  Adoptive immunotherapy: Within 2-3 days after completion of cytoreductive chemotherapy,
           patients receive CTLs IV over 1-2 hours on days 0, 4, 11, 21, and 28 in the absence of
           unacceptable toxicity. Patients with evidence of persistent disease on or after day 35
           OR relapsed disease after an initial response to CTLs receive a sixth infusion of CTLs
           followed, no more than 24 hours later, by interleukin-2 subcutaneously once daily for up
           14 total doses in the absence of unacceptable toxicity. Patients with subsequent
           relapsed disease after day 48 may be eligible for retreatment.

      After completion of study treatment, patients are followed with bone marrow aspiration every
      3 months for 1 year.

      PROJECTED ACCRUAL: A total of 25-30 patients (10-15 with acute myeloid leukemia or
      myelodysplastic syndromes AND 10-15 with acute lymphoblastic leukemia) will be accrued for
      this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vivo persistence of adoptively transferred T cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration of adoptively transferred T cells to the bone marrow</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antileukemic activity</measure>
  </secondary_outcome>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Undergoing allogeneic hematopoietic stem cell transplantation* from a major
             histocompatability complex (MHC)-identical related donor for 1 of the following:

               -  Primary refractory acute myelogenous leukemia (AML) or acute lymphoblastic
                  leukemia (ALL)

               -  AML or ALL beyond first remission

               -  Therapy-related AML at any stage

               -  Philadelphia chromosome (bcr-abl)-positive p190-positive ALL at any stage

               -  Acute leukemia at any stage arising from myelodysplastic syndromes or
                  myeloproliferative disorders, including any of the following:

                    -  Chronic myelomonocytic leukemia

                    -  Chronic myelogenous leukemia

                    -  Polycythemia vera

                    -  Essential thrombocytosis

                    -  Agnogenic myeloid metaplasia with myelofibrosis

               -  Refractory anemia with excess blasts

               -  Refractory anemia with excess blasts in transformation NOTE: *Patients must be
                  enrolled on study prior to undergoing transplantation

          -  Relapsed disease post-transplantation, as evidenced by 1 of the following criteria:

               -  Morphologic relapse, as defined by 1 or more of the following:

                    -  Peripheral blasts in the absence of growth factor therapy

                    -  Bone marrow blasts &gt; 5% of nucleated cells

                    -  Extramedullary chloroma or granulocytic sarcoma

               -  Flow cytometric relapse, as defined by the appearance of cells with abnormal
                  immunophenotype consistent with leukemia relapse in the peripheral blood or bone
                  marrow (detected before transplantation)

               -  Cytogenetic relapse, as defined by the appearance in 1 or more metaphases from
                  bone marrow or peripheral blood cells of either a non-constitutional cytogenetic
                  abnormality detected in at least 1 cytogenetic study performed before
                  transplantation OR a new abnormality known to be associated with leukemia

               -  Molecular relapse, as defined by 1 of the following:

                    -  1 or more positive polymerase chain reaction (PCR) assays for clonotypic
                       immunoglobulin heavy chain or T-cell receptor gene rearrangement in patients
                       transplanted for B- or T-cell ALL respectively

                    -  1 or more positive post-transplantation reverse transcription PCR assays for
                       p190 BCR-ABL mRNA fusion transcripts in patients transplanted for
                       Philadelphia chromosome-positive p190-positive ALL

          -  No grade III or IV acute graft-versus-host disease (GVHD)**

          -  No extensive chronic GVHD** NOTE: **At time of post-transplant relapse

        PATIENT CHARACTERISTICS:

        Age

          -  14 and over (patients &lt; 14 years of age may be eligible if they are deemed to be of
             sufficient height and weight by the pediatric attending physician)

        Performance status

          -  Karnofsky 60-100% (at time of post-transplant relapse)

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  No preexisting major nonhematopoietic organ toxicity â‰¥ grade 3 (at time of
             post-transplant relapse)

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Concurrent immunosuppressive steroid therapy for GVHD allowed provided both of the
             following are true:

               -  Able to taper steroid dose to &lt; 0.5 mg/kg/day

               -  No increase of &gt; 1 grade in acute GVHD OR progression of chronic GVHD within 14
                  days after dose change

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edus H. Warren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2010</last_update_posted>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>T-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>B-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

